期刊文献+

血脂康对颈动脉粥样硬化患者血管内皮功能及氧化还原平衡的影响 被引量:5

Effect of xuezhikang on vascular endothelial function and redox balance in patients with carotid atherosclerosis
原文传递
导出
摘要 目的探讨血脂康对颈动脉粥样硬化患者调脂作用及对血管内皮功能和血浆氧化还原平衡的影响。方法选择来我院心内科住院的颈动脉粥样硬化患者108例,随机分为血脂康组(54例)和考来烯胺组(54例),分别测定两组患者治疗12周前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、一氧化氮(NO)、内皮素1(ET-1)、还原型谷胱甘肽(GSH)和氧化型谷胱甘肽(GsSG),并根据Nernst方程计算GSH/GSSG氧化还原电位。结果治疗12周后,TC、I,DL—C和TG血脂康组从治疗前的(5.68±1.47、3.43±1.36、1.73±0.66)mmol/L降低到治疗后的(3.94±1.36、2.28±1.11、1.54±0.59)mmol/L(t值分别为3.915、4.160、2.187,P值分别为〈0.01、0.01、0.05),考来烯胺组(5.73±1.52、3.37±1.35、1.72±0.67)mmol/L降低到治疗后的(4.15±1.29、2.56±1.06、1.69±0.57)mmol/L(t值分别为3.760、4.035、1.893,P值分别为〈0.01、0.01、〉0.05);血脂康组ET-1、GssG、GsSGjGsH从[(154.43±63.06)ng/L(33.93±1.74)umol/L、-142.3±4.3]降低到[(121.71±59.11)ng/L、(30.42±1.59)umol/L、-146.1±4.4(t值分别为2.168、2.325、4.168.P值分别为〈0.05、0.05、0.01)];NO、NO/ET-1、GSH、GSH/GSSG从(48.41±16.53)umol/L、033±0.16、(286.11±38.23)umol/L、8.65±1.18升高到(64.40±18.86)umol/L、0.54±0.19、(321.27±56.47)umol/L、10.56±1.70(t值分别为3.725、3.987、3.894、4.168,P值分别为〈o.01、0.01、0.01、0.01)。结论对颈动脉粥样硬化患者,血脂康和考来烯胺均可有效调脂,但仅血脂康对血管内皮功能有一定的保护作用,且可使氧化还原平衡向还原方向偏移。 Objective To explore the effect of xuezhikang on blood lipids, vascular endothelial function and redox balance in patients with carotid atheroselerosis. Methods A total of 108 inpatients with carotid atherosclerosis in cardiology department were randomly divided into two groups: xuezhikang group (n=54) and cholestyramin group (n=54). Before and after treatment, the levels of total cholesterol (TC), triglyceride (TG), tow density lipoprotein cholesterol (LDL C), nitric oxide (NO), endothelin 1 (ET 1), reduced glutathione (GSH) and oxidized glutathione (GSSG) of all patients were measured. The GSH/GSSG as redox potentials were calculated according to Nernst equation. Results After 12 weeks of treatment, the levels of blood lipids were lower than before treatment in xuezhikang group (TC: (3.94±1.36) mmol/L vs. (5.68±1.47) mmol/L; LDL C.. (2.28±1.11) mmol/L vs. (3.43±1.36) mmol/L; TG: (1.54±0.59) mmol/L vs. (1.73± 0.66) mmol/L; t=3.915, 4.160, 2.187; P〈0.01, 0.01, 0.05, respectively], and the levels of blood lipids also decreased in cholestyramin group (TC: (4.15 ± 1.29) mmol/L .vs. (5.73 ± 1.52) mmol/L; LDL-C: (2. 56±1. 06) mmol/L vs. (3.37±1.35) mmol/L; TG: (1. 69±0. 57) mmol/L vs. (1.72±0.67) mmol/L; t=3. 760, 4.035, 1.893; P〈0. 01, 0.01, 〉0.05, respectively]. In xuezhikang group, ET-1, GSSG and GSSG/GSH ratios decreased significantly [(121.71±59.11) ng/ L vs. (154.43±63.06) ng/L; (30.42±1.59) umol/L vs. (33.93±1.74) umol/L; -146.1±4.4 vs. -142.3±4.3; t=2.168, 2.325, 4.168; P〈0.05, 0.05, 0.01, respectively), and NO, NO/ ET-1 ratios, GSH and GSH/GSSG increased significantly [ ( 64.40 ± 18.86 ) umol/L vs. ( 48.41 ± 16.53) umol/L; (0.54±0.19) vs. (0.33±0. 16); (321. 27±56.47) umol/L vs. (286. 11±38.23) umol/L; (10.56±1.70) vs. (8.65±1.18); t=3.725, 3.987, 3.894, 4.168; all P〈0.01]. Conclusions For patients with carotid atherosclerosis, both xuezhikang and cholestyramin could lower blood lipids efficiently, but only xuezhikang could protect vascular endothelial function partly, and makes plasma redox imbalance shift the balance.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2010年第5期370-373,共4页 Chinese Journal of Geriatrics
关键词 血脂康 颈动脉粥样硬化 内皮素-1 一氧化氮 谷胱甘肽 Xuezhikang Carotid alherosclerosis Nitric oxide Endothelin-1 Glutathione
  • 相关文献

参考文献9

  • 1寇文镕.血脂康基础研究现况概述.见:陆宗良,赵水平,叶平,主编.临床血脂研究新进展.北京:中华医学电子音像出版社,2005.106-114.
  • 2Labreuche J,Touboul PJ,Amarenco P.Plasma triglyceride levels and risk of stroke and carotid atherosclerosis:a systematic review of the epidemiological studies.Atherosclerosis,2009,203:331-345.
  • 3Halvorsen DS,Johnsen SH,Mathiesen EB,et al.The association between inflammatory markers and carotid atherosclerosis is sex dependent:the Tromso Study.Cerebrovasc Dis,2009,27:392-397.
  • 4Wang JS,Lee T,Chow SE.Role of exercise intensities in oxidized low-density lipoprotein-mediated redox status of monocyte in men.J Appl Physiol,2006,101:740-744.
  • 5张湘瑜,屈晓冰,彭孝立.老年人脂蛋白相关磷脂酶A2与冠心病冠状动脉病变程度及危险因素的关系[J].中华老年医学杂志,2009,28(11):901-904. 被引量:5
  • 6Polidori MC,Pratico D,Parente B,et al.Elevated lipid peroxidation biomarkers and low antioxidant status in atherosclerotic patients with increased carotid or iliofemoral intima media thickness.J Investig Med,2007,55:163-167.
  • 7Bonithon-KoppC,Coudray C,Berr C,et al.Combined effects of lipid peroxidation and antioxidantstatus on carotid atherosclerosis in a population aged 59-71 y:The EVA Study 1,2.Am J Clinic Nutr,1997,65:121-127.
  • 8Findrik Z,Vrsalovic Presecki A,Vasic-Racki D.Mathematical modelling of NADH oxidation catalyzed by new NADH oxidase from Lactobacillus brevis in continuously operated enzyme membrane reactor.J Biosci Bioeng,2007,104:275-280.
  • 9Modrego PJ,Rios C,Perez-Trullen JM,et al.Carotid intima-media thickness as a predictor of response to cholinest erase inhibitors in Alzheimer's disease:an open-label trial.CNS Drugs,2009,23:253-260.

二级参考文献15

  • 1刘甲兴,郑兴,秦永文,丁继军,赵仙先,曹江.脂蛋白相关性磷脂酶A_2活性能反映冠状动脉粥样硬化病变程度[J].第二军医大学学报,2006,27(4):391-395. 被引量:31
  • 2马梅,刘克强,齐新,何丽华,张东玲,孟东.脂蛋白相关磷脂酶A_2对冠心病患者诊断的临床意义研究[J].中国分子心脏病学杂志,2007,7(3):159-163. 被引量:3
  • 3Abuzeid AM, Hawe E, Humphries SE, et al. HIFMECH Study Group. Association between the Ala379Val variant of the lipoprotein associated phospho-lipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis, 2003, 168 : 283 -288.
  • 4Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983, 51: 606.
  • 5Natalie K, Wolfgang K. Predicting the risk of cardiovascular disease : where does lipoprotein associated phospho-lipase A2 fit in? Molecular Diagnosis & Therapy, 2007, 11: 203-217.
  • 6Yang EH, MeConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol, 2006, 26: 106-110.
  • 7Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol, 2006, 26: 2523-2529.
  • 8Mannheim D, Hermann J, Yersari D, et al. Enhanced expression of Lp PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaque. Stroke, 2008, 39 : 1448-1455.
  • 9Koenig W, Twardella D, Brenner H, et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamie stress. Arterioscler Thromb Vasc Biol, 2006, 26:1586-1593.
  • 10Brilakis ES, McConnell JP, Ryan J. Lennon RJ, et al. Association of Iipoprotein-assoeiated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J, 2005, 26, 137- 144.

共引文献4

同被引文献135

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部